IL-22/IL-22R1 pathway enhances cholangiocarcinoma progression via ERK1/2 activation

Figure 1 Aberrant expression of IL-22R1 in cholangiocarcinoma cell Lines, human and rat bile ducts, and cancer tissues. A: Expression of IL-22R1 in human bile duct tissues and cholangiocarcinoma tissues (from left to right: HE staining, immunohistochemical results for CK19, immunohistochemical results for IL-22R1); Expression of IL-22R1 in rat bile duct tissues and cholangiocarcinoma tissues (TAA-induced; from left to right: HE staining, immunohistochemical results for CK19, immunohistochemical results for IL-22R1); B: Western blot analysis showing IL-22R1 expression in RBE, HuCCT1, and HIBEpiCs cells; C: Quantitative analysis of the relative expression of IL-22R1 in RBE, HuCCT1, and HIBEpiCs cells based on Western blot results. The expression in RBE and HuCCT1 is higher than that in HIBEpiCs cells; D: Quantitative analysis of the relative mRNA expression of IL-22R1 in RBE, HuCCT1, and HIBEpiCs cells. The expression in RBE and HuCCT1 is higher than that in HIBEpiCs cells; E: Expression of IL22R1 gene in various cancer samples extracted from the UCSC database. The expression in cholangiocarcinoma is higher than that in adjacent normal tissues. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001, ^dP < 0.0001.